MSK-PCa2: Human Prostate Cancer Organoids

Description

Organoid cultures recapitulated the adenocarcinoma features, and IHC showed the cells were diffusely positive for AR and pan-cytokeratin, matching the tumor sample. When grafted into the renal capsule of SCID mice, the tumors were histologically indistinguishable from the metastatic lesion and stained diffusely positive for pan-cytokeratin and AR. The established organoid line exhibits a double time of 3 days.

Source

MSK-PCa2 is derived from patient who presented with metastatic adenocarcinoma. He had a short-term response to ADT for 6-months and developed an expanding hip metastasis requiring arthroplasy.

Inventors

  • Yu Chen, MD, PhD,  Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
  • Dong Gao, PhD, formerly at Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center

Key References

Gao D, et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell,  2014;159(1):176-87.

Licensing Information

This organoid cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

 

Stage of Development

Ready to use

Indications